Showing 4831-4840 of 5771 results for "".
- SECO 20/20 Unveils Exclusive Lineup of “Special Sessions”https://modernod.com/news/seco-20-20-unveils-exclusive-lineup-of-special-sessions/2477292/SECO 20/20 has announced the list of 11 speakers who will be featured during the event’s Special Sessions. From March 4-8, 2020, SECO 20/20 will bring together optometric professionals from around the globe to discuss the latest innovations, while discovering cutting-edge lab techniques and infor
- Aerpio Pharmaceuticals Presents New Data Showing Potential of Topical Ocular Formulation of AKB-9778 When Combined with Prostaglandinhttps://modernod.com/news/aerpio-pharmaceuticals-presents-new-data-showing-potential-of-topical-ocular-formulation-of-akb-9778-when-combined-with-prostaglandin/2477289/Aerpio Pharmaceuticals announced that Kevin Peters, MD, Aerpio’s Chief Scientific Officer, presented data from the fifth cohort of subjects from a phase 1b trial showing the potential of a topical ocular formulation of AKB-9778, a VE-PTP inhibitor and Tie2 activator, to lower IOP with minimal con
- Adverum Reports New Interim Data from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-reports-new-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477288/Adverum Biotechnologies announced new interim clinical data from the OPTIC phase 1 dose-ranging clinical trial of ADVM-022 intravitreal injection gene therapy. OPTIC includes treatment-experienced patients with wet age-related macu
- Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Deviceshttps://modernod.com/news/santen-and-verily-establish-joint-venture-to-develop-and-commercialize-unique-ophthalmic-devices/2477285/Santen Pharmaceutical and Alphabet subsidiary Verily announced the establishment of a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology. The new joint venture is driven by a mission to improve eye health for people everywhere, starting by
- Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DRhttps://modernod.com/news/regeneron-eylea-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-dr/2477283/Regeneron Pharmaceuticals announced positive 2-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection 2 mg (0.05 mL) in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The data were presented for the first time at the Angiogen
- Oxurion Presentation of Positive Topline Data from a Phase 1 Study Evaluating THR-687 for the Treatment of DMEhttps://modernod.com/news/oxurion-presentation-of-positive-topline-data-from-a-phase-1-study-evaluating-thr-687-for-the-treatment-of-dme/2477284/Oxurion NV announced that further positive topline data from a phase 1 study with THR-687, a novel, potent, pan-RGD integrin antagonist for the treatment of diabetic macular edema (DME), was presented by Arshad Khanani, MD, MA, Director of Clinical Research at Sierra Eye Associates, Reno, Nevada,
- Nicox to Present NCX 470 Phase 2 Results at Glaucoma 360 New Horizons Forumhttps://modernod.com/news/nicox-to-present-ncx-470-phase-2-results-at-glaucoma-360-new-horizons-forum/2477281/Nicox SA today announced that Tomas Navratil, PhD, Executive Vice President, Head of R&D of Nicox group, and General Manager of Nicox Ophthalmics, Inc, will present results from the NCX 470 Dolomites phase 2 clinical trial in the session “New Horizons in Pharmaceuticals” at the Glaucoma 360 N
- ProQR Therapeutics Teams Up With Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker Program for People With Inherited Retinal Diseaseshttps://modernod.com/news/proqr-therapeutics-teams-up-with-foundation-fighting-blindness-and-blueprint-genetics-to-support-the-my-retina-tracker-program-for-people-with-inherited-retinal-diseases/2477280/ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced its participation in the Foundation Fighting Blindness My Retina Tracker Program, a collaborative, open-access program run by Blueprint Geneti
- Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-selects-agc-biologics-as-lead-manufacturer-of-tthx1114-for-treatment-of-corneal-diseases/2477274/AGC Biologics, a global Contract Development and Manufacturing Organization for Biopharmaceuticals, and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound, TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore
- Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Projecthttps://modernod.com/news/acucela-meets-with-nasa-and-trish-for-phase-1-update-for-ss-oct-project/2477272/Acucela announced that the company was invited to meet with NASA and the Translational Research Institute for Space Health (TRISH)1 to present the status of its Swept Source-OCT (SS-OCT) device being developed for NASA’s Deep Space missions. The purpose of the meeting, which too